Hemolytic Disease of the Fetus and Newborn

Maternal IgG that crosses the placenta and coats fetal red cells can produce anemia before birth and hyperbilirubinemia after delivery. ABO and D typing plus an antibody screen identify many pregnancies at risk from non-ABO antibodies. Newborn testing and the bilirubin and hemoglobin trends remain necessary because a negative maternal antibody screen does not exclude ABO hemolytic disease.¹

Maternal antibody transfer to the fetal circulation

Small volumes of fetal red cells commonly cross into the maternal circulation, and the frequency of detectable transfer rises with gestational age.¹ Amniocentesis, chorionic villus sampling, and abdominal trauma all increase the chance of a larger fetomaternal hemorrhage, although most episodes remain small.¹ Because every fetal antigen foreign to the mother was inherited from the father, who contributes only one allele, the fetal antigen dose corresponds to heterozygous expression.

The immune response to D varies by exposure and patient. Large experimental transfusion exposures produced high sensitization rates, while modern clinical cohorts report lower rates and substantial variation.^2,3 Without Rh immune globulin prophylaxis, a D-negative mother carrying a D-positive fetus has a roughly 13-16% risk of forming anti-D after delivery; routine postpartum and antepartum prophylaxis reduce that risk markedly.⁴

Only IgG crosses the placenta, through neonatal Fc receptor (FcRn)-mediated transport that is detectable from about 13 weeks, becomes substantial during the second trimester, and reaches its maximum near term.⁵ All four IgG subclasses cross, but IgG1 and IgG3 are substantially more efficient at driving red-cell hemolysis than IgG2 and IgG4, so disease severity depends on the maternal subclass distribution as well as on antibody presence; subclass alone does not predict severity.^5,6

Antibody-coated fetal cells are cleared extravascularly by fetal splenic macrophages at a rate set by antibody titer, specificity, and fetal red-cell antigen density. The fetal marrow accelerates erythropoiesis and releases nucleated erythroblasts into the circulation, the finding that gave the disease its historical name, erythroblastosis fetalis. When marrow output can no longer keep pace, erythropoiesis expands into the liver and spleen, producing hepatosplenomegaly. Severe anemia combined with hypoproteinemia from reduced hepatic synthesis can progress to high-output cardiac failure with generalized edema, effusions, and ascites, a condition called hydrops fetalis. Hydrops has appeared as early as 18 to 20 weeks of gestation, and before modern intervention it was almost uniformly fatal.^7,8 Hemolysis continues after birth for as long as maternal IgG persists in the newborn’s circulation. Because IgG has a half-life of about 25 days, hemolysis can continue for days to weeks even though no new maternal antibody is being delivered.⁵

Bilirubin handling differs before and after birth. Hemoglobin released by red-cell destruction is converted to unconjugated bilirubin, which crosses the placenta and is conjugated and excreted by the maternal liver, so elevated fetal bilirubin alone does not cause fetal disease. After delivery this placental route disappears. The newborn liver, especially in a premature infant, conjugates bilirubin poorly, so unconjugated bilirubin accumulates and, if untreated, can cross into the central nervous system as kernicterus.^1,9

ABO incompatibility between mother and fetus is partially protective. The presumed mechanism is that when a group O mother carries a group A or B fetus, maternal anti-A and anti-B hemolyze ABO-incompatible D-positive fetal cells before the immune system recognizes D, and both the rate of detectable fetomaternal hemorrhage and the rate of D immunization fall.⁴ ABO incompatibility reduces risk but never replaces prophylaxis.

Disease-associated antibody specificities

D is the most immunogenic red-cell antigen, which is why D-negative blood is reserved for D-negative females of childbearing potential.²

Maternal testing through pregnancy

Baseline and repeat screening

ABO and D typing plus an antibody screen are performed early in pregnancy, together with a history of prior pregnancies, their outcomes, and transfusions. Previous severe hemolytic disease places the current pregnancy at high risk regardless of the present antibody level. The screen uses a validated indirect antiglobulin method capable of detecting clinically significant antibodies; the laboratory’s approved cells, method, and enhancement system define its sensitivity.¹³

Repeat testing follows obstetric and laboratory policy. A common schedule repeats ABO and D typing and the antibody screen at 28 weeks, with the sample from an eligible D-negative patient collected before antenatal Rh immune globulin. Additional testing may be needed after transfusion, a sensitizing event, or a previous unexpected antibody.¹³

Antibody identification in pregnancy

Cold-reactive IgM specificities such as anti-I, anti-IH, anti-Le^a, anti-Le^b, and anti-P1 usually need no HDFN follow-up when they behave as expected. Lewis antibodies are common in pregnancy and are not recognized causes of disease. Anti-M and anti-N may be IgM, IgG, or a mixture; sulfhydryl reagents reduce disulfide bonds and disrupt IgM while preserving IgG reactivity, which helps determine whether an IgG component is present.¹

Passive anti-D can remain detectable for months after Rh immune globulin, typically fading within three to six months, and no single laboratory test cleanly separates passive from immune anti-D. Interpret any anti-D result with the pre-Rh immune globulin antibody screen, the dose and timing of prior Rh immune globulin, the test method, and the serial trend. Reaction strength alone is unreliable, and prophylaxis continues when immune anti-D has not been established.¹³ An apparent anti-C plus anti-D pattern may instead be anti-G or anti-C plus anti-G. A reference laboratory should resolve this pattern because a patient with anti-G and no immune anti-D remains eligible for Rh immune globulin.¹³ Beyond anti-D, the specificities most often clinically significant in pregnancy are anti-K, anti-E, anti-c, anti-C, and anti-Fy^a.¹

Paternal and fetal genotyping

Testing the father’s phenotype, or his DNA-based genotype and zygosity for the corresponding antigen, can narrow the workup substantially. Only about 9% of people of European ancestry carry K, so excluding paternal K positivity ends the concern entirely; the frequency is lower in other populations.¹⁴ When the father is heterozygous or his testing is unavailable, fetal antigen status can be determined invasively by chorionic villus sampling at about 10 to 13 weeks or by amniocentesis from about 15 weeks. In an alloimmunized pregnancy, amniocentesis is preferred over chorionic villus sampling because it carries a lower risk of worsening fetomaternal hemorrhage.¹⁵

Testing cell-free fetal DNA in maternal plasma avoids an invasive procedure, but available assays, validated antigens, and eligible populations vary. Published United States validation includes D, C, c, E, K, and Fy^a. SMFM’s 2026 statement keeps amniocentesis as the standard fetal antigen test when an alloimmunized patient’s partner is heterozygous or unavailable. Cell-free DNA may be offered after counseling when the patient declines diagnostic testing or empiric monitoring; a presumed antigen-negative result does not by itself establish that surveillance can stop. SMFM does not recommend this approach for a prior pregnancy affected by HDFN, a clinically significant non-D alloantibody, or a known weak-D or other nondeletion RHD variant. Routine fetal D screening is not recommended for a nonalloimmunized D-negative patient when Rh immune globulin is readily available, although it may be considered with counseling and local policy during a shortage.¹⁵

Titration and the critical titer

Titer follows the relative concentration of an antibody capable of crossing the placenta. Serial samples are tested by the same validated method, with the stored previous sample tested in parallel when possible. Results from different methods or laboratories are not interchangeable, so each laboratory defines a significant change and communicates the method used.¹³

A critical titer is the method- and laboratory-validated titer at which the obstetric service begins fetal-anemia surveillance. It is not a universal number, and no single titer distinguishes passive from immune anti-D. A 2025 clinical guideline defines a critical titer of 16 for most antibodies and 4 for anti-K, while a previous affected fetus or neonate warrants surveillance regardless of the current titer. Anti-K should prompt early fetal-medicine planning because its relationship with anemia is less predictable than that of many other antibodies.^13,16 MCA-PSV above 1.5 multiples of the median (MoM) is a screening threshold for moderate-to-severe fetal anemia. Amniotic-fluid bilirubin analysis by delta OD450 is a historical method and is not used to diagnose fetal anemia.¹⁷

Worked example. An anti-D titration remains reactive through 1:16 but is nonreactive at 1:32, so the reported titer is 16. Whether that result is critical depends on the laboratory’s validated method and threshold rather than on a universal cutoff. On follow-up, the same method gives a titer of 64 with the original frozen specimen tested in parallel.

The change from 16 to 64 is a fourfold increase, equivalent to two doubling dilutions, and is assessed against the laboratory’s significant-change criterion together with the patient’s obstetric history.

Fetal assessment and intrauterine management

Fetal anemia lowers blood viscosity, which raises flow velocity in the fetal middle cerebral artery. Color Doppler locates the vessel, and pulsed-wave spectral Doppler measures peak systolic velocity near the artery’s origin with the insonation angle kept as close to zero as possible. The result is plotted against a gestational-age reference curve. In a pregnancy with an antigen-positive or antigen-unknown fetus that has reached the critical titer, current consensus begins weekly surveillance by 16 weeks.^16,17 MCA-PSV replaced amniotic-fluid delta OD450 as the primary noninvasive monitoring tool, and delta OD450 survives only as a historical method.¹⁷

Cordocentesis is ultrasound-guided needle sampling of the umbilical vein at its placental insertion. It yields fetal blood for direct testing: hemoglobin, hematocrit, bilirubin, blood type, direct antiglobulin test (DAT), and antigen phenotype or genotype. A repeatedly elevated MCA-PSV above 1.5 MoM or fetal hydrops should prompt expert fetal-therapy evaluation, with preparation for fetal blood sampling and intrauterine transfusion when clinically appropriate.¹⁷

Intrauterine transfusion infuses donor red cells directly into the umbilical vein through the cordocentesis needle. The transfusion decision and the post-transfusion target follow confirmed anemia, gestational age, post-transfusion hematocrit, and the fetal-therapy protocol. The next procedure is scheduled from the hematocrit response and surveillance findings; current consensus continues necessary transfusions through the end of the 35th week when technically feasible. Because transfused cells suppress the fetal marrow’s own production, the neonate may need additional transfusion in the first weeks after birth.¹⁶ All three fetal procedures, cordocentesis, intrauterine transfusion, and amniocentesis, carry risk of infection, preterm labor, and placental trauma. Placental trauma can worsen maternal sensitization by increasing fetomaternal hemorrhage, which is why invasive fetal procedures in a previously unsensitized D-negative patient also count as Rh immune globulin indications.¹

For intrauterine transfusion, donor red cells are crossmatch-compatible with maternal plasma, ABO compatible with the mother and fetus, antigen-negative for the maternal antibody, hemoglobin S negative, irradiated, and leukocyte-reduced or otherwise CMV-risk-reduced according to policy. A hematocrit of about 75% to 80% corrects severe anemia in a small volume.^18,19

Neonatal evaluation

Serologic testing

Newborn ABO antigens are not fully developed, so forward typing may react more weakly than in older children, and reverse grouping cannot confirm the ABO group because newborns lack their own isoagglutinins; any anti-A or anti-B in neonatal serum is maternal in origin.¹⁹ D typing can occasionally yield a false-negative result called blocked D, when the infant’s red cells are so heavily coated with maternal anti-D that reagent anti-D cannot bind additional sites. An eluate may identify the bound antibody as anti-D, and the infant’s true D status is determined by a validated antibody-removal and retyping method or by molecular testing.²⁰

The DAT with anti-IgG is the most important diagnostic test for immune hemolysis in the newborn, but its strength does not correlate well with disease severity, and a positive DAT can occur without clinical hemolysis, for example after maternal antenatal Rh immune globulin.^9,21 Routine elution on every DAT-positive infant is unnecessary. Elution is valuable when clinically important hemolysis is present and the antibody specificity is uncertain, including suspected ABO HDFN or a blocked-D typing result.¹⁹

Cord blood hemoglobin provides a useful baseline without removing additional blood from the infant. Interpret it by gestational and postnatal age, then follow the clinical and laboratory trend. Transfusion decisions also weigh symptoms, respiratory support, the cause of anemia, and the applicable neonatal protocol.^22,23

Component selection

Group O red cells are commonly used for intrauterine and exchange transfusion when compatible with the mother and infant, and red cells for exchange may be resuspended in compatible plasma to limit the ABO antibody transfused. For routine neonatal transfusion, select units that are ABO and D compatible with the mother and infant, lack the antigen corresponding to every clinically significant maternal antibody, and are IAT crossmatch-compatible with maternal plasma when it is available. Prematurity alone is not an indication for irradiation; exchange and routine neonatal transfusions follow different component specifications in the laboratory’s policy.¹⁹

Treatment escalation

Phototherapy at 460 to 490 nm converts unconjugated bilirubin into configurational and structural photoisomers that are less lipophilic and less neurotoxic, and it is sufficient for most mild-to-moderate cases.²⁴ Intravenous immune globulin (IVIG) competes with maternal antibody for Fc receptors on splenic macrophages. For infants at least 35 weeks’ gestation with DAT-positive isoimmune hemolytic disease, the AAP states that IVIG may be considered when bilirubin reaches the escalation-of-care threshold and continues to rise despite intensive phototherapy. Benefit is uncertain, adverse effects are possible, and IVIG must not delay exchange transfusion.⁹ Exchange transfusion, which replaces the neonate’s circulating blood volume, is now rarely required. When used, it removes unconjugated bilirubin to prevent kernicterus, residual maternal antibody, and antibody-coated cells. Infants born before 35 weeks require gestational-age-specific thresholds and a neonatal protocol outside the scope of the AAP guideline cited here.⁹

Rh immune globulin prophylaxis

Rh immune globulin supplies passive anti-D to prevent active maternal immunization to D. Proposed mechanisms include rapid removal of D-positive fetal cells from the maternal circulation and suppression of D-specific B-cell activation; no single mechanism fully explains the protective effect.²⁵

Without prophylaxis, a D-negative mother carrying a D-positive fetus has a roughly 13-16% chance of forming anti-D after delivery. Postpartum prophylaxis lowers the risk to about 0.5-1.8%, and adding routine antepartum prophylaxis lowers it further to about 0.14-0.2%. Even a small fetal-cell exposure can immunize a susceptible patient, and the dose needed for an exposure cannot be inferred from whether anti-D is detectable.^4,26

Indications

An unsensitized patient who is D-negative, or has a D variant managed as being at risk for anti-D, usually receives routine antenatal prophylaxis at 26 to 28 weeks. The antibody-screen sample is collected before prophylaxis. If delivery does not occur within 12 weeks of that dose, the product label calls for another dose to maintain protection. Prophylaxis is also considered after an event that can introduce fetal cells, including invasive fetal testing or therapy, antepartum bleeding, abdominal trauma, external cephalic version, pregnancy loss, or accidental exposure to D-positive red cells. Gestational age, event type, immune status, product label, and local obstetric policy determine the dose and whether hemorrhage quantitation is needed.^26,27

After delivery, an eligible mother whose infant is D-positive or whose D status cannot be established should receive Rh immune globulin as soon as possible and within 72 hours. A missed dose requires prompt clinician and transfusion-service review under the applicable product label and local policy; the missed 72-hour target should not be treated as a reason to take no action.^4,26,27

For an unsensitized patient after abortion or pregnancy loss before 12 weeks, ACOG’s 2024 Clinical Practice Update suggests forgoing routine D testing and Rh immune globulin. The Society for Maternal-Fetal Medicine disagrees and recommends offering D testing and prophylaxis when feasible. Neither statement substitutes for event-specific guidance for ectopic pregnancy, invasive treatment, or another distinct sensitizing event.^28,29

Deciding whether and how much to give

The postpartum pathway is conditional:

1. Establish the mother’s D status. A clearly D-positive patient does not need anti-D prophylaxis. A weak, partial, discrepant, or indeterminate D result requires molecular testing or management under the laboratory’s D-variant policy. AABB considers weak D types 1, 2, 3, and 4.1 not at risk for anti-D; other variants may be managed as D-negative.²⁶
2. Determine whether anti-D is immune. Confirmed immune anti-D makes prophylaxis ineffective. Documented passive anti-D after prophylaxis, or anti-D whose status remains uncertain, does not by itself make the patient ineligible.^13,27
3. Test the infant for D, including a serologic weak-D test when the initial result is D-negative. Prophylaxis is unnecessary only when both results are negative. An unavailable, indeterminate, discrepant, or blocked-D result is managed as D-positive or unknown until resolved.²⁶
4. For an eligible mother with a D-positive or D-unknown infant, obtain the maternal hemorrhage specimen after delivery and before Rh immune globulin at the interval specified by the laboratory. Do not delay an otherwise indicated dose while waiting for quantitation.
5. Use a rosette screen only when the maternal and infant D results make that test valid. Maternal D variants, blocked D, a D-unknown infant, or another source of unreliable reactivity requires a quantitative method instead. A valid negative screen supports one standard dose; a positive or unsuitable screen is followed by Kleihauer-Betke testing or flow cytometry and dose calculation.²⁶

Maternal anti-D strength or titer does not measure fetomaternal hemorrhage volume and is not used to calculate the postpartum dose.^13,26,27

Quantifying large hemorrhages

The laboratory specifies when to collect the postpartum maternal specimen so fetal cells have mixed into the circulation while prophylaxis can still be given promptly. A rosette screen detects D-positive fetal cells in a clearly D-negative mother and therefore depends on valid maternal and infant D results. It can miss a weakly expressed fetal D antigen or produce misleading reactivity when the mother has a D variant.²⁶

The Kleihauer-Betke test acid-treats and counterstains a maternal smear. Fetal cells retain stain because they contain acid-resistant fetal hemoglobin, while most maternal cells appear as pale ghosts. The laboratory’s validated counting and calculation procedure converts the fetal-cell percentage to an estimated hemorrhage volume. Maternal F cells can produce a falsely high estimate, and differences in staining and counting add imprecision. Flow cytometry can provide a more precise measurement when available, although an anti-hemoglobin F assay must still account for maternal F cells.²⁶

One 300 microgram (1,500 IU) dose covers 30 mL of D-positive whole blood or 15 mL of D-positive red cells. The current RhoGAM label directs the calculated result to be rounded up to the next whole syringe.^26,27

Worked example. A laboratory’s validated Kleihauer-Betke procedure finds 52 fetal cells among 2,000 cells counted and uses the common whole-blood estimate of fetal-cell percentage multiplied by 50.

Fetal-cell percentage = 52 ÷ 2,000 = 2.6%

Estimated fetomaternal hemorrhage = 2.6 × 50 = 130 mL of fetal whole blood

Vials before rounding = 130 ÷ 30 = 4.33

Round 4.33 up to the next whole syringe: 5 doses of 300 micrograms each. The laboratory follows its validated formula and the label for the product actually supplied.

Dosing and administration

A standard United States dose is 300 micrograms (1,500 IU), covering 15 mL of D-positive red cells or 30 mL of D-positive whole blood. The labeled 50 microgram (250 IU) dose covers 2.5 mL of red cells or 5 mL of whole blood when that product and dose are appropriate for an early-pregnancy event. Local policy must follow current obstetric guidance as well as the product label.^26,27,28

Route is product-specific. RhoGAM and MICRhoGAM are labeled for intramuscular use; some other anti-D products permit intravenous or intramuscular administration. Contraindications and warnings also differ by product. The presence of a small amount of IgA calls for product-specific assessment of IgA deficiency, anti-IgA, and prior severe reactions, rather than an automatic class-wide contraindication.^26,27

Pitfalls

Rh immune globulin cannot prevent anti-D formation once immune anti-D is established. Passive and immune anti-D are separated with the pre-dose result, timing and dose of prophylaxis, test method, history, and serial behavior; no single reaction strength or titer proves the distinction. While the status remains uncertain, an otherwise eligible patient continues to receive prophylaxis. Maternal D variants and a newborn’s blocked-D result require resolution under the laboratory’s policy. Rh immune globulin is administered to the mother, never to the newborn.^13,26,27

ABO hemolytic disease

Maternal IgG anti-A, anti-B, or anti-A,B can cross the placenta and bind ABO-incompatible fetal red cells. Severe fetal anemia is rare. The usual concern is hemolysis with early neonatal hyperbilirubinemia; jaundice during the first 24 hours requires prompt bilirubin measurement and clinical evaluation.^9,30

ABO disease is usually mild because ABO antigens are not fully developed on fetal and neonatal red cells. Antigen expression increases after birth and approaches adult levels at about 2 to 4 years. Neonatal red cells therefore offer fewer A or B sites for antibody binding. Maternal IgG concentration, subclass, antigen density, and neonatal bilirubin handling all contribute, so a high maternal titer does not determine an individual infant’s course.^30,31 Neonatal ABO typing uses reagents and methods validated for weak antigen expression.¹

High-titer IgG anti-A,B occurs more often in group O individuals than in group A or B individuals, so most ABO HDFN affects a group A or B infant of a group O mother. Rare cases occur with a non-O mother. Naturally occurring ABO antibodies can be present before pregnancy, allowing a first pregnancy to be affected, and recurrence and severity vary between pregnancies.^1,30,31

Microspherocytes are common on the neonatal smear in ABO HDFN, while severe Rh-system disease more often produces marked anemia and circulating erythroblasts. DAT strength and eluate reactivity do not measure clinical severity. Follow the bilirubin rate of rise, hemoglobin or hematocrit, reticulocyte count, smear, feeding, gestational age, and other neurotoxicity risk factors. Phototherapy is usually sufficient. For a DAT-positive infant at least 35 weeks’ gestation, IVIG is considered only under the restricted AAP circumstances described above.^9,30,31

Maternal ABO antibody class and titer have limited value for prenatal prediction, so ABO disease is diagnosed after birth, and no single test establishes it. Obtain the infant’s blood type and DAT when the maternal antibody screen is positive or unknown, or when the clinical course warrants testing. For an infant of a group O D-positive mother with a negative antibody screen, testing may be omitted when reliable bilirubin surveillance and follow-up are available. Interpret the DAT with the bilirubin trajectory and evidence of hemolysis. Cord blood collection by venipuncture can be used when testing is indicated, with care to avoid contamination by maternal blood or Wharton’s jelly.^9,23

References

1. Bloch EM, Campbell-Lee S, McKenna DH Jr, et al, eds. Technical Manual. 22nd ed. AABB; 2026. ISBN 978-1-56395-557-0. Accessed August 28, 2026.
2. Avent ND, Reid ME. The Rh blood group system: a review. Blood. 2000;95(2):375-387. doi:10.1182/blood.V95.2.375.
3. Ji Y, Luo G, Fu Y. Incidence of anti-D alloimmunization in D-negative individuals receiving D-positive red blood cell transfusion: a systematic review and meta-analysis. Vox Sang. 2022;117(5):633-640. doi:10.1111/vox.13232.
4. American College of Obstetricians and Gynecologists. Practice Bulletin No. 181: prevention of Rh D alloimmunization. Obstet Gynecol. 2017;130(2):e57-e70. Reaffirmed 2026. doi:10.1097/AOG.0000000000002232.
5. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. doi:10.1155/2012/985646.
6. Velkova E. Correlation between the amount of anti-D antibodies and IgG subclasses with severity of haemolytic disease of foetus and newborn. Open Access Maced J Med Sci. 2015;3(2):293-297. doi:10.3889/oamjms.2015.058.
7. Moise KJ Jr. Considerations and approaches for early onset fetal anemia due to red cell alloimmunization. Best Pract Res Clin Obstet Gynaecol. 2025;100:102602. doi:10.1016/j.bpobgyn.2025.102602.
8. Hall V, Vadakekut ES, Maines J, Avulakunta ID. Hemolytic disease of the fetus and newborn. In: StatPearls. StatPearls Publishing; updated January 22, 2025. Accessed August 28, 2026.
9. Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150(3):e2022058859. doi:10.1542/peds.2022-058859.
10. Daniels G, Poole J, de Silva M, Callaghan T, MacLennan S, Smith N. The clinical significance of blood group antibodies. Transfus Med. 2002;12(5):287-295. doi:10.1046/j.1365-3148.2002.00399.x.
11. Vaughan JI, Manning M, Warwick RM, Letsky EA, Murray NA, Roberts IAG. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med. 1998;338(12):798-803. doi:10.1056/NEJM199803193381204.
12. Smart E, Armstrong B. Blood group systems. ISBT Sci Ser. 2020;15(suppl 1):123-150. doi:10.1111/voxs.12593.
13. Regan F, Veale K, Robinson F, et al. Guideline for the investigation and management of red cell antibodies in pregnancy: a British Society for Haematology guideline. Transfus Med. 2025;35(1):3-23. doi:10.1111/tme.13098.
14. Dean L. The Kell blood group. In: Blood Groups and Red Cell Antigens. National Center for Biotechnology Information; 2005. Accessed August 28, 2026.
15. Rink BD, Kuller JA, Sparks TN, et al; Society for Maternal-Fetal Medicine. Society for Maternal-Fetal Medicine Statement: evaluation and management of cell-free DNA screening for fetal red cell antigen genotype in alloimmunized and non-alloimmunized pregnancies. Pregnancy. 2026;2(4):e70339. doi:10.1002/pmf2.70339.
16. Moise KJ Jr, Markham KB, Spinella PC, et al. A clinical practice guideline for the management of pregnancy alloimmunized to red blood cell antigens. JAMA Netw Open. 2025;8(11):e2544649. doi:10.1001/jamanetworkopen.2025.44649.
17. Mari G, Norton ME, Stone J, et al; Society for Maternal-Fetal Medicine. SMFM Clinical Guideline #8: the fetus at risk for anemia: diagnosis and management. Am J Obstet Gynecol. 2015;212(6):697-710. doi:10.1016/j.ajog.2015.01.059.
18. Vikraman SK, Krishnan M. SFM Fetal Therapy Practice Guidelines: intrauterine blood transfusion. J Fetal Med. 2023;10(4):187-194. Published online March 21, 2024. doi:10.1055/s-0044-1779752.
19. New HV, Berryman J, Bolton-Maggs PHB, et al; British Committee for Standards in Haematology. Guidelines on transfusion for fetuses, neonates and older children. Br J Haematol. 2016;175(5):784-828. doi:10.1111/bjh.14233.
20. Wang H, Chen J, Jiang Y. A case of a newborn with blocked RhD antigen and hemolytic disease of the fetus and newborn. Lab Med. 2017;48(4):381-383. doi:10.1093/labmed/lmx061.
21. Bahr TM, Tweddell SM, Zalla JM, et al. Neonatal and obstetrical outcomes of pregnancies complicated by alloimmunization. Pediatrics. 2024;153(6):e2023064604. doi:10.1542/peds.2023-064604.
22. Jopling J, Henry E, Wiedmeier SE, Christensen RD. Reference ranges for hematocrit and blood hemoglobin concentration during the neonatal period: data from a multihospital health care system. Pediatrics. 2009;123(2):e333-e337. doi:10.1542/peds.2008-2654.
23. Kaufman DA, Lucke AM, Cummings JJ; American Academy of Pediatrics Committee on Fetus and Newborn. Postnatal cord blood sampling: clinical report. Pediatrics. 2025;155(6):e2025071811. doi:10.1542/peds.2025-071811. Corrected in: Pediatrics. 2026;157(5):e2026076151. doi:10.1542/peds.2026-076151.
24. Bhutani VK, Wong RJ, Turkewitz D, Rauch DA, Mowitz ME, Barfield WD. Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation: technical report. Pediatrics. 2024;154(3):e2024068026. doi:10.1542/peds.2024-068026.
25. Brinc D, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology Am Soc Hematol Educ Program. 2009;2009(1):185-189. doi:10.1182/asheducation-2009.1.185.
26. AABB. Association Bulletin #24-02: Use of Rh Immune Globulin and Considerations in the Setting of Supply Shortages and Limited Availability. July 15, 2024. Accessed August 28, 2026.
27. Kedrion Biopharma Inc. RhoGAM Ultra-Filtered PLUS and MICRhoGAM Ultra-Filtered PLUS [prescribing information]. Revised July 2025. Accessed August 28, 2026.
28. American College of Obstetricians and Gynecologists. Rh D immune globulin administration after abortion or pregnancy loss at less than 12 weeks of gestation: clinical practice update. Obstet Gynecol. 2024;144(6):e140-e143. doi:10.1097/AOG.0000000000005733.
29. Prabhu M, Louis JM, Kuller JA, et al; Society for Maternal-Fetal Medicine. Society for Maternal-Fetal Medicine Statement: RhD immune globulin after spontaneous or induced abortion at less than 12 weeks of gestation. Am J Obstet Gynecol. 2024;230(5):B2-B5. doi:10.1016/j.ajog.2024.02.288.
30. Jajosky RP, Wu SC, Zheng L, et al. ABO blood group antigens and differential glycan expression: perspective on the evolution of common human enzyme deficiencies. iScience. 2023;26(1):105798. doi:10.1016/j.isci.2022.105798.
31. Wiener AS, Freda VJ, Wexler IB, Brancato GJ. Pathogenesis of ABO hemolytic disease. Am J Obstet Gynecol. 1960;79(3):567-592. doi:10.1016/0002-9378(60)90259-3.